United Advisor Group LLC Sells 7,285 Shares of Bristol Myers Squibb Company (NYSE:BMY)

United Advisor Group LLC lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 35.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,106 shares of the biopharmaceutical company’s stock after selling 7,285 shares during the quarter. United Advisor Group LLC’s holdings in Bristol Myers Squibb were worth $799,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BMY. Pinney & Scofield Inc. acquired a new position in Bristol Myers Squibb in the fourth quarter worth about $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $26,000. Global Wealth Strategies & Associates grew its holdings in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Transce3nd LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $28,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Down 0.9%

BMY opened at $46.82 on Thursday. The firm has a market capitalization of $95.29 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company has a fifty day moving average price of $48.35 and a 200-day moving average price of $54.52. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) earnings per share. Bristol Myers Squibb’s revenue for the quarter was down 5.6% on a year-over-year basis. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.30%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 92.88%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BMY shares. Argus upgraded shares of Bristol Myers Squibb to a “hold” rating in a research report on Friday, April 25th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective for the company. Finally, UBS Group dropped their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.